Patients with kidney cancer to pay only 10% of Nexava NHI price.

The NHI reimbursement of Nexava, a new oral anti-kidney cancer drug (sorafenib) and first in its kind in the world, has been approved by the MOHW. Now, the patient may pay only 10% of the drug charges under the NHI coverage. The NHI price for Nexava 200mg tablet is 25,486 won/T taking effects from April 1 this year.
Nexava was first approved by the U. S. FDA in Dec. 2005 for the treatment of k...